Growth Disorders Growth Hormone Short-Acting Products Preferred Specialty Management Policy
Customize your policy alerts
Sign up for Cigna Policy PSM027 alerts
Get alerted when Policy PSM027 changes without checking for updates manually.
Monitor payer policy activity
This policy governs preferred-product selection and exception review for short-acting somatropin products under Cigna-administered health benefit plans. Patients must meet the applicable standard prior authorization criteria, and non-preferred products generally require prior trial and intolerance of preferred products.
A preferred specialty management program was established for short-acting growth hormone products.
Saizen was removed from the policy as obsolete.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.